{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:51:55Z","timestamp":1773913915939,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T00:00:00Z","timestamp":1512691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Flow cytometric immunophenotyping (FCI) is an integral part in the diagnosis and classification of hematologic malignancies. FCI results also influence therapeutic decisions and disease prognosis. ClearLLab LS is a 12\u2010antibody 10\u2010color cocktail provided in dry format designed as a screen for patients suspected of having hematolymphoid disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A blinded comparison between ClearLLab LS, (CD8\u2010FITC, Kappa\u2010FITC,CD4\u2010PE, Lambda\u2010PE, CD19\u2010ECD, CD56\u2010PE\u2010Cy5.5, CD10\u2010PE\u2010Cy7, CD34\u2010APC, CD5\u2010APC\u2010A700, CD20\u2010APC\u2010A750, CD3\u2010PB, and CD45\u2010KrO), ClearLLab Reagents (five\u2010color, 17\u2010antibodies) and individual Laboratory Developed Tests (LDTs), was conducted at four laboratories. Evaluation of ClearLLab LS was performed on 210 specimens, compared to the five\u2010color ClearLLab Reagents (IVD and CE\u2010IVD), and a subset (<jats:italic>n<\/jats:italic>\u2009=\u2009167) to LDTs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ClearLLab LS showed good agreement to ClearLLab Reagents in detecting the absence (104\/104) or presence (106\/106) of abnormal populations. Of specimens with abnormal populations the ClearLLab LS agreed with the ClearLLab Reagent for neoplasm maturity assessment (70\/70 mature and 36\/36 immature). Out of 167 specimens with LDTs results, 86 contained abnormal population(s), ClearLLab LS detected 82 (95.3%) of cases. Of the 4 cases not detected by ClearLLab LS, 3 were plasma cell neoplasms and 1 was a mature T cell malignancy. Eighty\u2010one samples with no hematological malignancy as analyzed by LDT were also negative by ClearLLab LS (100% agreement). ClearLLab LS agreed with LDTs assessment of neoplasms' maturity (55\/55 mature and 27\/27 immature).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ClearLLab LS screening tube showed excellent agreement between ClearLLab Reagents and with LDT's. The presence of CD34 and CD10 in the tube allowed the detection of blast populations in several acute leukemias and myeloid neoplasms that were tested. \u00a9 2017 International Clinical Cytometry Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.21603","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T15:52:56Z","timestamp":1511538776000},"page":"863-869","source":"Crossref","is-referenced-by-count":13,"title":["Initial flow cytometric evaluation of the Clearllab lymphoid screen"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0851","authenticated-orcid":false,"given":"B.D.","family":"Hedley","sequence":"first","affiliation":[{"name":"Pathology and Laboratory Medicine, London Health Sciences Center London Ontario, N6A 5W9 Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Clinical Research, Beckman Coulter, Inc. Miami 33196 Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Luider","sequence":"additional","affiliation":[{"name":"Calgary Laboratory Services Calgary T2N 2T9 Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Kern","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory Munich 81377 Bavaria Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lozanski","sequence":"additional","affiliation":[{"name":"The Ohio State University Columbus 43210 Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Chin\u2010Yee","sequence":"additional","affiliation":[{"name":"Department of Medicine Schulich School of Medicine Western University of Ontario London N6K 5W9 Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.E.","family":"Lowes","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, London Health Sciences Center London Ontario, N6A 5W9 Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Keeney","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, London Health Sciences Center London Ontario, N6A 5W9 Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Careaga","sequence":"additional","affiliation":[{"name":"Clinical Research, Beckman Coulter, Inc. Miami 33196 Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Magari","sequence":"additional","affiliation":[{"name":"Clinical Research, Beckman Coulter, Inc. Miami 33196 Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tejidor","sequence":"additional","affiliation":[{"name":"Clinical Research, Beckman Coulter, Inc. Miami 33196 Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.120"},{"key":"e_1_2_6_3_1","unstructured":"Leukemia and Lymphoma Society Facts 2015\u20132016. New York: Leukemia and Lymphoma Society;2016."},{"key":"e_1_2_6_4_1","unstructured":"American Cancer Society Cancer Facts and Figures. Georgia: American Cancer Society;2016."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-120535"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21251"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21402"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12678"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12368"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21107"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21105"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21104"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21106"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21108"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.122"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_6_17_1","unstructured":"SwerdlowS Campo E Harris NL Jaffe ES Pileri SA Stein H Thiele J Vardiman JW.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed. Lyon: International Agency for Research on Cancer;2008."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.700"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471142956.cy0629s54"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20774"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.21603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.21603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T01:27:26Z","timestamp":1694654846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.21603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/cyto.b.21603"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.21603","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}